An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for broader availability to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view custom-mixed peptide therapies, which have drawn steady interest from users seeking alternatives to conventional drugs. Researchers say peptide treatments could change approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of six peptides paves the way for more expanded prescribing, even as skeptics warn of limited evidence. Market watchers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on certain peptide candidates.